BSECompany UpdateResults7 Nov 2026
Brawn Biotech Ltd
NEWSPAPER PUBLICATION FOR UN-AUDITED FINANCIAL RESULTS FOR QUARTER AND HALF YEAR ENDED 30TH SEP 2026
Brawn Biotech Ltd has published its unaudited financial results for the quarter and half year ended 30th September 2026. The company's financial performance is not explicitly stated in the announcement, but it appears to be a routine disclosure of financial results.
BSECompany UpdateRegulatory5 Nov 2026
Brawn Biotech Ltd
Intimation regarding non-applicability of regulation 23(9)
Brawn Biotech Ltd has submitted an undertaking to the BSE, stating that the company is not required to file related party transactions as per Regulation 23(9) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, due to its paid-up share capital and net worth not exceeding Rs. 10 crore and Rs. 25 crore, respectively, as on March 31, 2026.
BSEResultResults5 Nov 2026
Brawn Biotech Ltd
Outcome of Board Meeting
Brawn Biotech Ltd has announced its un-audited financial results for the quarter and half year ended September 30, 2026, with revenue from operations at Rs. 61,274.78 lakhs and profit from ordinary activities before tax at Rs. 18.46 lakhs.
BSEBoard MeetingResults5 Nov 2026
Brawn Biotech Ltd
Outcome Of Board Meeting Held On 5th November, 2026 To Consider And Approve, Inter-Alia, Un-Audited Financial Results Of The Company For Quarter Ended September 30, 2026.
Brawn Biotech Ltd has announced its un-audited financial results for the quarter and half-year ended September 30, 2026. The company reported a profit from ordinary activities before tax of ₹18.46 lakhs and a profit for the period of ₹18.46 lakhs. The results were reviewed by the audit committee and approved by the board of directors on November 5, 2026.
BSEBoard MeetingResults29 Oct 2026
Brawn Biotech Ltd
Brawn Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve Un-Audited Financial Results Of The Company For The Quarter Ended September 30, 2026
Brawn Biotech Ltd has informed BSE that its Board of Directors will meet on November 5, 2026, to consider and approve the un-audited financial results for the quarter ended September 30, 2026. The trading window will remain closed from October 29 to November 16, 2026.
BSECompany Update15 Oct 2026
Brawn Biotech Ltd
Intimation under Reg 74(5)
Brawn Biotech Ltd has submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, as required by the BSE.
BSECompany UpdateAuditor Change29 Sept 2026
Brawn Biotech Ltd
Disclosure under Regulation 30 of SEBI LODR Regulations, 2015
Brawn Biotech Ltd has announced the appointment of M/s. GDSM and Co. as its statutory auditors and the re-appointment of Mr. Brij Raj Gupta as a director, both of which were approved by the company's members.
BSEAGM/EGMResults29 Sept 2026
Brawn Biotech Ltd
Scrutinizers Report attached along with voting results for 41st AGM
Brawn Biotech Ltd has announced the voting results and scrutinizer's report for its 41st Annual General Meeting (AGM) held on September 29, 2026, through video conferencing. All items of business were approved by the members, and the details of voting results are enclosed in the prescribed format.
BSEAGM/EGM29 Sept 2026
Brawn Biotech Ltd
Proceedings of 41st AGM
Brawn Biotech Ltd held its 41st Annual General Meeting (AGM) on September 29, 2026, through video conferencing. The meeting was attended by 44 members, and the resolutions related to audited financial statements, director appointment, statutory auditor appointment, and managerial remuneration were passed.
BSEAGM/EGM29 Sept 2026
Brawn Biotech Ltd
Outcome of 41st Annual General Meeting
Brawn Biotech Ltd held its 41st Annual General Meeting on September 29, 2026, through VC/OAVM, and all resolutions were passed with a requisite majority.
BSEInsider Trading / SASTResults28 Sept 2026
Brawn Biotech Ltd
Closure of Trading Window for quarter ended 30.09.2026
Brawn Biotech Ltd has announced the closure of its trading window for insiders from October 1, 2026, until 48 hours after the declaration of un-audited financial results for the quarter and half year ended September 30, 2026.
BSECompany Update2 Sept 2026
Brawn Biotech Ltd
Letters sent to shareholders as per Reg 36
Brawn Biotech Ltd has issued letters to shareholders who have not registered their email address, providing a weblink for accessing the Notice of the 41st Annual General Meeting and Annual Report for the financial year 2025-26.
BSECompany Update2 Sept 2026
Brawn Biotech Ltd
Newspaper Publication for 41st Notice of AGM.
Brawn Biotech Ltd has published a newspaper advertisement for its 41st Annual General Meeting (AGM) to be held on September 29, 2026, through video conferencing. The company has also been involved in a copyright dispute related to an AI-generated artwork, with the Copyright Office rejecting the application for registration of the artwork as the AI system, DABUS, is not recognized as the legal author under Indian copyright law.
BSEOthersResults1 Sept 2026
Brawn Biotech Ltd
ANNUAL REPORT FOR FY 2025-26
Brawn Biotech Ltd has released its annual report for FY 2025-26, along with the notice of its 41st Annual General Meeting. The meeting will be held on September 29, 2026, through video conferencing. The report includes the audited financial statements, directors' report, and other relevant information.
BSEAGM/EGMResults1 Sept 2026
Brawn Biotech Ltd
Notice of 41st AGM to be held on 29.09.2026
Brawn Biotech Ltd has announced the notice of its 41st Annual General Meeting (AGM) to be held on 29th September 2026. The meeting will consider the audited financial statements for the financial year ended 31st March 2026, appointment of a director, and managerial remuneration of Mr. Amit Kumar.
BSECompany UpdateResults14 Aug 2026
Brawn Biotech Ltd
Publication of Un-audited financial results for the quarter ended June 30, 2026.
Brawn Biotech Ltd has published its un-audited financial results for the quarter ended June 30, 2026, in compliance with Regulation 47 of SEBI (Listing Obligation and Disclosure Requirements), 2015.
BSEResultResults13 Aug 2026
Brawn Biotech Ltd
Outcome of Board Meeting held on August 13, 2026 to consider and approve, inter-alia, un-audited financial results of the company for quarter ended June 30, 2026.
Brawn Biotech Ltd has announced its un-audited financial results for the quarter ended June 30, 2026, which were approved by the Board of Directors in a meeting held on August 13, 2026. The company reported revenue from operations of ₹ 217.18 crore, a decrease of 0.53% from the previous quarter. The net profit for the quarter stood at ₹ 4.05 crore, a decrease of 56.25% from the previous quarter.
BSEBoard MeetingResults13 Aug 2026
Brawn Biotech Ltd
Outcome of Board Meeting held on August 13, 2026 to consider and approve, inter-alia, un-audited financial results of the company for quarter ended June 30, 2026.
Brawn Biotech Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at ₹ 217.18 crore and profit before tax at ₹ 4.15 crore. The company's board of directors has approved the financial results and also considered and approved the Boards' Report for the financial year ended March 31, 2026.
BSEBoard MeetingResults5 Aug 2026
Brawn Biotech Ltd
Brawn Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve Un-Audited Financial Results ....
Brawn Biotech Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 to consider and approve Un-Audited Financial Results for the quarter ended June 30, 2026.